Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies: a EuroFlow study

Verbeek, M.W.C.; Buracchi, C.; Laqua, A.; Nierkens, S.; Sedek, L.; Flores-Montero, J.; ... ; Velden, V.H.J. van der (2021)

Article / Letter to editor

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

• acute leukaemia
• diagnostic haematology
• flow cytometry
• minimal residual disease

• All authors: Verbeek, M.W.C.; Buracchi, C.; Laqua, A.; Nierkens, S.; Sedek, L.; Flores-Montero, J.; Hofmans, M.; Costa, E.S. de; Novakova, M.; Mejstrikova, E.; Barrena, S.; Kohlscheen, S.; Szczepanowski, M.; Kulis, J.; Oliveira, E.; Jugooa, R.; Jong, A.X. de; Szczepanski, T.; Philippe, J.; Dongen, J.J.M. van; Orfao, A.; Bruggemann, M.; Gaipa, G.; Velden, V.H.J. van der
• Date: 2021-12-08
• Journal: British Journal of Haematology
• Volume: 197
• Issue: 1
• Pages: 76 - 81
• DOI: doi:10.1111/bjh.17992
• Link: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.17992